Inventor · disambiguated record
Benson M. Fong
Also filed as: FONG BENSON M
2 granted patents·7 pending applications·10 citations·filing 2004–2013
58Inventor score
Technology areasA61P
Top patents by PatentIndex Score
9 records- 0178US7893050B2Fasudil in combination therapies for the treatment of pulmonary arterial hypertensionASAHI KASEI PHARMA CORP·Filed 2006·Granted Feb 22, 2011·7 cites·8 claims
- 0267US8476259B2Fasudil in combination therapies for the treatment of pulmonary arterial hypertensionFONG BENSON M·Filed 2012·Granted Jul 2, 2013·3 cites·8 claims
- 0342US2014031372A1Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndromeCOTHERIX INC·Filed 2013·Application pending·0 cites
- 0442US2011171139A1Fasudil in combination therapies for the treatment of pulmonary arterial hypertensionASAHI KASEI PHARMA CORP·Filed 2011·Application pending·0 cites
- 0541US2005043391A1Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndromeFiled 2004·Application pending·0 cites
- 0640US2005113314A1Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndromeFiled 2004·Application pending·0 cites
- 0738US2012289542A1Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndromeFONG BENSON M·Filed 2012·Application pending·0 cites
- 0834US2011071111A1Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndromeFONG BENSON M·Filed 2010·Application pending·0 cites
- 0932US2011250142A1Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndromeFONG BENSON M·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Benson M. Fong files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →